BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 15480668)

  • 1. Autologous stem cell transplantation in hematological malignancies.
    Gorin NC
    Springer Semin Immunopathol; 2004 Nov; 26(1-2):3-30. PubMed ID: 15480668
    [No Abstract]   [Full Text] [Related]  

  • 2. [The impact of stem cell therapy in hematology and oncology].
    Marks R; Finke J
    Internist (Berl); 2006 May; 47(5):467-8, 470-8. PubMed ID: 16557411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous peripheral blood stem cell transplantation in the patients with hematologic malignancies and solid tumors.
    Ke X; Yang Y; Zhao X; Wang L
    Chin Med J (Engl); 2001 Feb; 114(2):196-9. PubMed ID: 11780206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma.
    Rugo HS; Damon LE; Ries CA; Wolf JL; Linker CA
    Prog Clin Biol Res; 1994; 389():505-11. PubMed ID: 7535460
    [No Abstract]   [Full Text] [Related]  

  • 5. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An analysis of double autologous hemopoietic stem cell transplantation for hematological malignancies].
    Zhang B; Huang W; Da W; Zhang Z; Yao S; Gao C; Han X; Wu X; Wang Q; Yu L; Zhang M; Jin H
    Zhonghua Yi Xue Za Zhi; 2002 Jan; 82(2):123-6. PubMed ID: 11953143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
    Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
    Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous bone marrow transplantation for leukemia.
    Stuart RK
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):40-54. PubMed ID: 8211215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The value of bone marrow transplantation in the treatment of leukemia].
    Ehninger G; Schuler U; Haas R
    Internist (Berl); 1993 Jun; 34(6):550-7. PubMed ID: 8101514
    [No Abstract]   [Full Text] [Related]  

  • 12. Rationale for purging in autologous stem cell transplantation.
    Gulati SC; Acaba L
    J Hematother; 1993; 2(4):467-71. PubMed ID: 7916249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third biannual report of the Cochrane Haematological Malignancies Group.
    Kober T; Skoetz N; Trelle S; Bohlius J; Engert A;
    J Natl Cancer Inst; 2005 Aug; 97(16):E2. PubMed ID: 16106014
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunologic methods of purging in autologous stem cell transplantation.
    Berkahn L
    J Hematother Stem Cell Res; 2000 Apr; 9(2):147-59. PubMed ID: 10813528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantity and origin of transplanted autologous blood cells are independent factors associated with speed of postransplant hematological reconstitution.
    Rogulj D; Batinić D; Nemet D; Petrovecki M
    Croat Med J; 1999 Sep; 40(3):404-8. PubMed ID: 10411969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma.
    Villanueva ML; Vose JM
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):521-30. PubMed ID: 17147239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
    Naparstek E
    Curr Hematol Rep; 2005 Jul; 4(4):276-83. PubMed ID: 16009042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment outcome of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies not in remission].
    Bao HY; Wu XJ; Ma X
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):156-7. PubMed ID: 22780938
    [No Abstract]   [Full Text] [Related]  

  • 19. Does in vitro bone marrow purging improve the outcome after autologous bone marrow transplantation?
    Lazarus HM; Rowe JM; Goldstone AH
    J Hematother; 1993; 2(4):457-66. PubMed ID: 8087496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex-vivo purging of hematopoietic progenitor cells.
    de Lima M; Shpall EJ
    Curr Hematol Rep; 2004 Jul; 3(4):257-64. PubMed ID: 15217555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.